Apoptose
Os inibidores da apoptose são compostos que previnem ou retardam o processo de morte celular programada, conhecido como apoptose. Esses inibidores são vitais no estudo dos mecanismos de sobrevivência celular e são usados para investigar doenças onde a apoptose é desregulada, como câncer, distúrbios neurodegenerativos e doenças autoimunes. Ao modular a apoptose, esses inibidores podem ajudar no desenvolvimento de terapias destinadas a controlar a morte celular. Na CymitQuimica, oferecemos uma ampla seleção de inibidores da apoptose de alta qualidade para apoiar sua pesquisa em biologia celular, oncologia e áreas relacionadas.
Subcategorias de "Apoptose"
- ASK(6 produtos)
- BCL(11 produtos)
- Caspase(125 produtos)
- FOXO1(3 produtos)
- IAP(66 produtos)
- Mdm2(12 produtos)
- PD-1/PD-L1(125 produtos)
- PDK(9 produtos)
- PERK(25 produtos)
- Serina/treonina quinase(15 produtos)
- Survivina(13 produtos)
- TNF(92 produtos)
- c-RET(51 produtos)
- p53(62 produtos)
Exibir 6 mais subcategorias
Foram encontrados 5592 produtos de "Apoptose"
Ordenar por
Pureza (%)
0
100
|
0
|
50
|
90
|
95
|
100
PI3K/AKT-IN-1
CAS:<p>PI3K/AKT-IN-1 is a dual inhibitor of PI3K and AKT with anti-cancer activity, inhibiting the PI3K/AKT pathway and inducing caspase 3-dependent apoptosis.</p>Fórmula:C23H23N5O4SPureza:99.84%Cor e Forma:SoildPeso molecular:465.53DHU-Se1
<p>DHU-Se1: potent anti-inflammatory, releases reactive selenium from macrophages, inhibits iNOS/TNF-α, blocks M0 to M1 polarization.</p>Fórmula:C23H23N3OSSeCor e Forma:SolidPeso molecular:468.47CHI-KAT8i5
CAS:<p>CHI-KAT8i5 is a selective inhibitor of KAT8 with a KD of 19.72 μM. It induces apoptosis (Apoptosis) in a dose-dependent manner. CHI-KAT8i5 can inhibit tumor growth in esophageal squamous cell carcinoma, colon cancer, melanoma, gastric cancer, non-small cell adenocarcinoma, and liver cancer.</p>Fórmula:C23H29N3O5S3Cor e Forma:SolidPeso molecular:523.688Topoisomerase IIα-IN-4
<p>Topoisomerase IIα-IN-4 (F2) is a non-intercalative ATP-competitive inhibitor of human DNA topoisomerase II, specifically inhibiting TopoIIα with an IC50 value</p>Fórmula:C25H21NO2Cor e Forma:SolidPeso molecular:367.44Tubulin inhibitor 17
<p>Compound 3b inhibits tubulin polymerization, IC50 12.38 µM, with anticancer properties and promotes cell apoptosis.</p>Fórmula:C17H16N2OCor e Forma:SolidPeso molecular:264.32PDEδ/NAMPT IN-1
CAS:<p>PDEδ/NAMPT IN-1 (Compound 17d) is a dual inhibitor targeting phosphodiesterase 6 (PDE6) with a dissociation constant (KD) of 0.410 nM and nicotinamide phosphoribosyltransferase (NAMPT) with an inhibitory concentration (IC50) of 2.21 nM. It disrupts KRAS-related signaling by inhibiting NAMPT's role in the synthesis of nicotinamide adenine dinucleotide (NAD+), consequently inducing apoptosis in pancreatic cancer cells with KRAS mutations. This compound holds potential for research in KRAS-mutant pancreatic cancer.</p>Fórmula:C26H30N4O4SCor e Forma:SolidPeso molecular:494.61FLT3/TrKA-IN-1
<p>FLT3/TrKA-IN-1: Potent dual kinase inhibitor for FLT3 & TrKA, promising for AML research.</p>Fórmula:C28H30N4O2Cor e Forma:SolidPeso molecular:454.56BRD-K56819078
CAS:<p>BRD-K56819078, a Bcl-2 inhibitor, significantly reduces the burden of senescent cells and the mRNA expression of aging-related genes in the kidneys. It exerts its anti-aging effects by inhibiting cell apoptosis (apoptosis).</p>Fórmula:C24H20FN3O4S2Cor e Forma:SolidPeso molecular:497.56Bcl-2-IN-3
CAS:<p>Bcl-2-IN-3 (Compound 10) is an inhibitor of Bcl-2, utilized in cancer research.</p>Fórmula:C16H16N2O4Cor e Forma:SolidPeso molecular:300.31Ac-DMLD-CMK
CAS:<p>Ac-DMLD-CMK is a peptide designed to target the caspase3-Gsdme signaling pathway in mice. It specifically inhibits the activation of caspase 3 and Gsdme, preventing the cleavage of Gsdme by caspase 3, which reduces pyroptosis. This process helps alleviate damage to renal tubular epithelial cells and decrease the secretion of inflammatory cytokines. Ac-DMLD-CMK can lower serum creatinine and blood urea nitrogen levels in mice induced by Cisplatin, thereby mitigating the progression of renal dysfunction. It holds potential for research into chemotherapy-induced nephrotoxicity.</p>Fórmula:C22H35ClN4O9SCor e Forma:SolidPeso molecular:567.053CDK-IN-9
<p>CDK-IN-9: A potent CDK inhibitor, gels to enhance CDK12/DDB1 binding, targets CDK2/E (IC50: 4 nM), induces apoptosis via dephosphorylation.</p>Fórmula:C21H24N8SCor e Forma:SolidPeso molecular:420.53PD-L1-IN-1
<p>PD-L1-IN-1, potent PD-L1 inhibitor with 115 nM IC50, suppresses tumors, boosts immune response, and spares healthy cells.</p>Fórmula:C21H23N5O2Cor e Forma:SolidPeso molecular:377.44Keap1-Nrf2-IN-4
<p>Keap1-Nrf2-IN-4 hinders MGC-803 cell growth (IC50=2.55μM), migration, and induces apoptosis with low toxicity.</p>Fórmula:C26H34N2OCor e Forma:SolidPeso molecular:390.56OICR12694
CAS:<p>OICR12694 (JNJ-65234637) is an orally active inhibitor of B cell lymphoma 6 (BCL6) .</p>Fórmula:C29H28ClF3N8O4Cor e Forma:SolidPeso molecular:645.03Spicamycin
CAS:<p>Spicamycin can be used as a potent inducer of differentiation of human myeloid leukemia cells (HL-60) and murine myeloid leukemia cells (M1).</p>Fórmula:C30H51N7O7Cor e Forma:SolidPeso molecular:621.77Antitumor agent-77
<p>Antitumor agent-77 suppresses cancer cell growth, migration, induces apoptosis, and hinders EMT.</p>Fórmula:C7H11F3N2O5PtCor e Forma:SolidPeso molecular:455.25HDAC-IN-81
CAS:<p>HDAC-IN-81 (Compound 11g) is an HDAC inhibitor capable of effectively inhibiting HDAC1 with an IC50 value of 4.5 nM. Additionally, it exhibits anticancer activity by inhibiting cell proliferation and can induce cell apoptosis (apoptosis).</p>Fórmula:C20H27N3O3Cor e Forma:SolidPeso molecular:357.45BRD-K20733377
CAS:<p>BRD-K20733377 is a Bcl-2 inhibitor that exhibits selective cytotoxicity toward senescent cells, specifically inhibiting the activity of etoposide-induced senescent IMR-90 cells with an IC50 of 10.7 μM. Additionally, BRD-K20733377 reduces the mRNA expression of aging-related genes p16, p21, and KI67 in aged mouse models.</p>Fórmula:C23H18N4O3SCor e Forma:SolidPeso molecular:430.48BRD-K44839765
CAS:<p>BRD-K44839765 selectively targets Bcl-2, exhibiting an IC50 of 5.6 μM in IMR-90 cells. This compound is also orally active.</p>Fórmula:C23H19N3O2S2Cor e Forma:SolidPeso molecular:433.55ZSH-512
CAS:<p>ZSH-512 is a potent inhibitor of RARγ with antiproliferative properties. It induces apoptosis and reduces the expression of CD133, NANOG, SOX2, and EPCAM proteins. ZSH-512 exhibits anticancer activity and shows potential for colorectal cancer research.</p>Fórmula:C20H21N3O3SCor e Forma:SolidPeso molecular:383.464TBC-1
CAS:<p>TBC-1 is a chlorophyll-a derivative that acts as a photosensitizer for photodynamic therapy (PDT). It efficiently generates type I ROS and targets the endoplasmic reticulum. TBC-1 demonstrates in vitro biocompatibility and PDT effectiveness under both normoxic and hypoxic conditions.</p>Fórmula:C31H28BrN3O3Cor e Forma:SolidPeso molecular:570.476NA-17
CAS:<p>NA-17 is a naphthalimide compound with antitumor activity and exhibits lower toxicity to normal cells such as HL-7702 and WI-38. It demonstrates p53-dependent inhibition selectivity in various NSCLC cells, inducing the accumulation of active p53 in the mitochondria and nuclei of these cells. NA-17 causes cell cycle arrest in the G1 phase and promotes apoptosis and cell death.</p>Fórmula:C26H27N3O4Cor e Forma:SolidPeso molecular:445.51Topoisomerase I/II inhibitor 8
CAS:<p>TopoisomeraseI/II inhibitor 8 (Compound Ru7) is a dual catalytic inhibitor of TopoisomeraseI/II that induces DNA damage and activates PARP-1, leading to the activation of RIPK1, RIPK3, and MLKL, ultimately causing necroptosis. It shows significant anticancer activity by effectively targeting cancer cell nuclei and inducing cell death through necroptosis, offering substantial clinical potential in overcoming resistance in cancer treatment.</p>Fórmula:C14H11Br2NO5S2Cor e Forma:SolidPeso molecular:497.179VNPP433-3β
CAS:<p>VNPP433-3β acts as a molecular glue degrader, targeting the androgen receptor (AR) and its splice variants (AR-Vs) as well as MAP kinase-interacting serine/threonine protein kinase Mnk1/2. It effectively inhibits the proliferation of cancer cells LNCaP, C4-2B, and CWR22Rv1, with GI50 values of 0.2, 0.3, and 0.31 μM, respectively. Additionally, VNPP433-3β shows favorable pharmacokinetics in CD-1 mice and suppresses tumor growth in the CWR22Rv1 xenograft mouse model.</p>Fórmula:C29H34N4Cor e Forma:SolidPeso molecular:438.61Claturafenib
CAS:<p>Claturafenib is a brain-permeable, selective, all-mutant BRAF inhibitor.PF-07799933 has shown antitumor activity, used in combination with MEK inhibitors.</p>Fórmula:C18H15Cl2F2N5O3SPureza:98.68% - 99.85%Cor e Forma:SolidPeso molecular:490.31Antitumor agent-184
CAS:<p>Antitumor Agent-184 (compound 12aa) triggers apoptosis in various cell lines, exhibiting IC50 values of 2.35 μM in B16-F10 cells, 7.32 μM in 4T1 cells, and 10.31 μM in CT26 cells.</p>Fórmula:C22H16N4O2SCor e Forma:SolidPeso molecular:400.45YCW-E11
CAS:<p>YCW-E11 is an antiapoptotic Bcl-2 family proteins inhibitor.</p>Fórmula:C25H21Cl2N3O6S2Pureza:98%Cor e Forma:SolidPeso molecular:594.49Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride
CAS:<p>Thalidomide-NH-amido-PEG2-C2-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate, comprised of a cereblon ligand based on Thalidomide and a linker, utilized in the synthesis of PROTACs.</p>Fórmula:C21H28ClN5O7Peso molecular:497.93Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride
CAS:<p>Thalidomide-NH-amido-PEG1-C2-NH2 hydrochloride is a synthetic E3 ligase ligand-linker conjugate that includes a thalidomide-based cereblon ligand and a linker, used in the synthesis of PROTAC.</p>Fórmula:C19H24ClN5O6Peso molecular:453.88Spliceostatin A
CAS:<p>Spliceostatin A is an anticancer agent and splicing inhibitor that induces apoptosis by inducing cell cycle arrest in the G1 and G2/M phases.</p>Fórmula:C28H43NO8Pureza:94.66%Cor e Forma:SolidPeso molecular:521.643TOPOI/PARP-1-IN-1
CAS:<p>Compound B6, also known as TOPOI/PARP-1-IN-1, is a dual inhibitor targeting TOPOI and PARP, exhibiting low cytotoxicity and oral activity with a PARP1 IC 50 of 0.09 μM. This compound effectively inhibits cancer cell proliferation and migration, induces cell cycle arrest at the G0/G1 phase, and triggers apoptosis. In murine models, TOPOI/PARP-1-IN-1 demonstrated a tumor growth inhibition rate (TGI) of 75.4% [1].</p>Fórmula:C36H38Br2N4O2Cor e Forma:SolidPeso molecular:718.52Tubulin/NRP1-IN-1
CAS:<p>Tubulin/NRP1-IN-1 (compound TN-2) serves as a dual inhibitor targeting both Tubulin and NRP1, exhibiting IC50 values of 0.71 μM and 0.85 μM, respectively. This compound notably reduces the viability of prostate tumor cell lines and triggers apoptosis [1].</p>Fórmula:C28H37N5O8Cor e Forma:SolidPeso molecular:571.62FLT3-IN-13
<p>FLT3-IN-13 inhibits topoisomerase II/FLT3 in leukemia with IC50 of 2.26 μM, causes G2/M arrest, and promotes apoptosis.</p>Fórmula:C20H14N4O2Cor e Forma:SolidPeso molecular:342.35Z-VA-DL-D-FMK
CAS:<p>Z-VA-DL-D-FMK (Z-VA-DL-D(OH)-FMK) acts as an inhibitor of caspases. It irreversibly binds to caspases, enhancing the sensitivity to TNF-α and stimulating HIV replication in infected T cells ACH-2.</p>Fórmula:C21H28FN3O7Cor e Forma:SolidPeso molecular:453.46ASP9831
CAS:<p>ASP9831 is an orally active PDE4 inhibitor. It suppresses LPS-induced TNF-α production and exhibits anti-inflammatory properties. ASP9831 is useful in the study of steatohepatitis.</p>Fórmula:C20H23N3O3Cor e Forma:SolidPeso molecular:353.42HDAC/PSMD14-IN-1
CAS:<p>HDAC/PSMD14-IN-1 is a derivative of gambogic acid. It serves as an orally active dual inhibitor targeting PSMD14 and HDAC1, with IC50 values of 238.7 nM and 141.2 nM, respectively. The compound exhibits significant cytotoxicity against ESCC cell lines (IC50: 30-250 nM) and effectively reverses epithelial-mesenchymal transition (EMT). Additionally, HDAC/PSMD14-IN-1 can induce apoptosis. In KYSE30 cell xenograft models in mice, it displays antitumor activity. HDAC/PSMD14-IN-1 is useful for researching esophageal cancer treatment.</p>Fórmula:C20H24N4O3S2Cor e Forma:SolidPeso molecular:432.56ASK1-IN-7
CAS:<p>ASK1-IN-7 (Compound 4c) is an ASK1 inhibitor and a derivative of the ASK1 inhibitor scaffold 5-(5-Phenyl-furan-2-ylmethylene)-2-thioxo-thiazolidin-4-one. This compound is potentially applicable in research involving ASK1 signaling pathways, including studies on cellular stress response, inflammatory response, neurodegenerative diseases, and cardiovascular diseases.</p>Fórmula:C13H8N2O2S2Cor e Forma:SolidPeso molecular:288.345MD102
CAS:<p>MD102, with an IC50 value of 0.35 μM, is a potent TG2 inhibitor that stabilizes p53 by inhibiting TG2. This results in a decrease in p-AKT and p-mTOR downstream signaling, ultimately inducing tumor cell apoptosis [1].</p>Fórmula:C13H4BrCl2FN2O2Cor e Forma:SolidPeso molecular:389.99Tubulin polymerization-IN-4
CAS:<p>Tubulin polymerization-IN-4: inhibits tubulin (IC50=4.6 μM), blocks G2/M phase, induces apoptosis, hinders cell cloning/migration, damages vasculature.</p>Fórmula:C21H21ClN2O4Cor e Forma:SolidPeso molecular:400.86HER2-IN-10
<p>HER2-IN-10 is a psoralen derivative that induces apoptosis. HER2-IN-10 shows anti-breast cancer activity and light-activated cytotoxicity [1].</p>Fórmula:C15H13NO5Cor e Forma:SolidPeso molecular:287.27DC-U4106
CAS:<p>DC-U4106: USP8 inhibitor, Kd 4.7μM, IC50 1.2μM, degrades Erα, low-toxicity tumor suppressor for breast cancer research.</p>Fórmula:C29H27N5O5Cor e Forma:SolidPeso molecular:525.56Anti-inflammatory agent 16
<p>Compound 14 is a peptidomimetic that significantly lowers TNFα, NO, CD40, and CD86, showcasing strong anti-inflammatory effects.</p>Fórmula:C21H23N5O3Cor e Forma:SolidPeso molecular:393.44SphK1-IN-2
<p>SphK1-IN-2: SphK1 inhibitor, IC50: 19.81 nM; less effective on SphK2. Induces apoptosis, hinders cancer cell growth.</p>Fórmula:C27H30BrNO4SCor e Forma:SolidPeso molecular:544.5VEGFR-IN-3
CAS:<p>VEGFR-IN-3 inhibits cancer cell growth (OVCAR-4, MDA-MB-468) with IC50s: 0.29, 0.35μM. Used in cancer research.</p>Fórmula:C27H28N2O6Cor e Forma:SolidPeso molecular:476.52Anticancer agent 45
<p>Anticancer agent 46, potent and selective, induces apoptosis, is cytotoxic to cancer cells, with low toxicity to human lymphocytes.</p>Fórmula:C22H14ClN3O6S2Cor e Forma:SolidPeso molecular:515.95EGFR-IN-47
<p>EGFR-IN-47: strong oral EGFRL858R/T790M/C797S blocker, induces cell death; promising for NSCLC research. IC50: 0.01 μM.</p>Fórmula:C29H35N7Cor e Forma:SolidPeso molecular:481.64PIM1-IN-3
<p>PIM1-IN-3 (HL8) selectively blocks PIM1, induces Colo320 cell apoptosis, and may be researched for cancer.</p>Fórmula:C27H25BrN6OCor e Forma:SolidPeso molecular:529.43HER2-IN-11
<p>HER2-IN-11 is a psoralen derivative that induces apoptosis. HER2-IN-11 shows light-activated cytotoxicity and also exhibits anti-breast cancer activity [1].</p>Fórmula:C17H11NO6Cor e Forma:SolidPeso molecular:325.27eIF4E-IN-4
CAS:<p>eIF4E-IN-4 (Compound 33) is a selective inhibitor of the eukaryotic initiation factor 4E (eIF4E) with a biochemical activity value of 95 nM. It inhibits cap-dependent mRNA translation with an IC50 of 2.5 μM and is applicable in research on breast cancer, colon cancer, and head and neck cancer.</p>Fórmula:C20H19ClN5O5PCor e Forma:SolidPeso molecular:475.822LSD1/ER-IN-1
<p>LSD1/ER-IN-1 inhibits ER & LSD1 (IC50: 1.55 μM), and fights MCF-7 breast cancer (IC50: 8.79 μM).</p>Fórmula:C23H18FNO6SCor e Forma:SolidPeso molecular:455.46
